Avanos Medical (NYSE:AVNS) Sees Strong Trading Volume - Here's What Happened

Key Points

• Acquisition: Avanos agreed to be acquired by affiliates of American Industrial Partners for $25.00 per share in cash (about $1.27B), representing roughly a 72% premium that delivers immediate value to public shareholders.
• Legal/closing risk: Multiple shareholder-law firms have launched investigations alleging potential unfair price or fiduciary breaches, which could delay the deal, increase costs, or pressure the board to seek a higher bid.
• Operational momentum and market activity: Avanos posted a Q4 beat (EPS $0.29 vs. $0.24 est.; revenue topped estimates), has seen institutional inflows with ~95% institutional ownership, and experienced unusually strong trading volume of about 1.09M shares (up 21%).

Shares of Avanos Medical, Inc. (NYSE:AVNS - Get Free Report) saw unusually-strong trading volume on Wednesday . Approximately 1,089,603 shares were traded during trading, an increase of 21% from the previous session's volume of 903,790 shares.The stock last traded at $24.6050 and had previously closed at $24.63.

More Avanos Medical News

Here are the key news stories impacting Avanos Medical this week:

• Positive Sentiment: Deal: Avanos agreed to be acquired by affiliates of American Industrial Partners for $25.00 per share in cash, valuing the company at ~ $1.27B — a ~72% premium that delivers immediate, certain value to public shareholders. Avanos Stock Surged on $1.27 Billion AIP Buyout Deal at 72% Premium
• Positive Sentiment: Operational signal: Avanos reported a Q4 beat (EPS $0.29 vs. $0.24 est.; revenue topped estimates) and retains institutional holders, which supports the narrative that the business has improving fundamentals behind the strategic transaction. Avanos Medical Posts Q4 Beat as Institutional Investors Like Armistice Capital Hold Positions in Non-Opioid Pain Device Segment
• Neutral Sentiment: Market coverage: Media outlets tracked the stock’s historic intraday surge and summarized deal terms and timing; this is informational but doesn’t change deal economics. AVNS stock records historic intraday surge – everything to know about the buyout deal by American Industrial Partners
• Negative Sentiment: Legal/closing risk: Multiple shareholder-law firms have launched investigations and alerts alleging potential unfair price or fiduciary breaches related to the sale; litigation or a challenge could delay closing, increase costs or pressure the board to seek a higher bid. $HAREHOLDER ALERT: The M-A Class Action Firm Announces An Investigation of Avanos Medical, Inc. NYSE: AVNS

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Zacks Research upgraded shares of Avanos Medical from a "strong sell" rating to a "hold" rating in a research report on Monday, January 26th. Weiss Ratings restated a "sell (d-)" rating on shares of Avanos Medical in a research report on Monday, December 22nd. Finally, Wall Street Zen upgraded shares of Avanos Medical from a "hold" rating to a "buy" rating in a research report on Saturday, March 28th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Reduce".

Avanos Medical Stock Performance

The company has a quick ratio of 1.26, a current ratio of 2.15 and a debt-to-equity ratio of 0.12. The company's 50-day moving average is $14.27 and its two-hundred day moving average is $12.61. The company has a market capitalization of $1.14 billion, a P/E ratio of -15.58 and a beta of 1.05.

Avanos Medical (NYSE:AVNS - Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.05. Avanos Medical had a negative net margin of 10.40% and a positive return on equity of 5.47%. The company had revenue of $180.90 million for the quarter, compared to analysts' expectations of $174.70 million. During the same period in the prior year, the business earned $0.43 earnings per share. Avanos Medical's revenue for the quarter was up .7% compared to the same quarter last year. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. Equities analysts anticipate that Avanos Medical, Inc. will post 1.32 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of AVNS. AQR Capital Management LLC grew its position in Avanos Medical by 46.4% during the first quarter. AQR Capital Management LLC now owns 192,864 shares of the company's stock valued at $2,700,000 after acquiring an additional 61,095 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Avanos Medical by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company's stock valued at $386,000 after acquiring an additional 1,121 shares during the last quarter. Millennium Management LLC grew its position in Avanos Medical by 508.3% during the first quarter. Millennium Management LLC now owns 547,740 shares of the company's stock valued at $7,849,000 after acquiring an additional 457,703 shares during the last quarter. Empowered Funds LLC grew its position in Avanos Medical by 5.4% during the first quarter. Empowered Funds LLC now owns 162,182 shares of the company's stock valued at $2,324,000 after acquiring an additional 8,348 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Avanos Medical by 17.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 140,810 shares of the company's stock valued at $2,018,000 after acquiring an additional 20,541 shares during the last quarter. 95.17% of the stock is currently owned by institutional investors.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company's products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.